SPARKS, NV / ACCESSWIRE / November 16, 2023 / Ludwig Enterprises, Inc., the Genomics Language Company™, focused on the development…
BMF-219 is an investigational novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure diabetesNew…
POLB 001 - a potential blockbuster immunomodulatorLONDON, UK / ACCESSWIRE / November 16, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or…
Partnership extends capability for trial imaging integration to Florence Healthcare's 18,000 activated clinical trial sites.ATLANTA, GA / ACCESSWIRE / November…
- Enrollment numbers rise to 239 in ongoing potentially pivotal study of Berubicin for treatment of GBM; Expected full enrollment…
TORONTO, ON / ACCESSWIRE / November 15, 2023 / StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS), an integrated healthcare…
Dr. Chinn retired as a Rear Admiral of the United States NavyMINNEAPOLIS--(BUSINESS WIRE)--Humanetics Corporation, a leading innovator in medical countermeasures,…
Aristotle and AVRT to be offered to My One Medical Source's Customer BaseTORONTO, ON / ACCESSWIRE / November 14, 2023…
The Company's ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Continues to ProgressPlanning for APVO436 Phase 2…
Net revenue increased 5% in Q3 2023 versus Q2 2023Top line results expected before Thanksgiving for company's phase 3 OnTarget…